Bio-Gene Technology Financing Cash Flow
The Net Financing Cash Flow of Bio-Gene Technology (BGT.AX) as of Oct 20, 2026 is 2.74 M AUD. In the previous year, Net Financing Cash Flow was 1.47 M AUD — a change of 86.41% (higher).
Get this data via API
Financial Data API
Financing Cash Flow
2.74 MAUD
YoY
86.41%
Last updated:
The Bio-Gene Technology Financing Cash Flow history
3 Years
10 Years
25 Years
Max
| YEAR | Financing Cash Flow | YoY |
|---|---|---|
| 2.74 MAUD | +86.41% | |
| 1.47 MAUD | -25.64% | |
| 1.98 MAUD | -2,738.63% | |
| -75,000.00AUD | -101.70% | |
| 4.41 MAUD | +1,737.80% | |
| 239,878.00AUD | -91.01% | |
| 2.67 MAUD | +227,282.35% | |
| 1,173.00AUD | -99.98% | |
| 6.53 MAUD | +86.93% | |
| 3.49 MAUD | +926.69% | |
| 340,200.00AUD | +19.58% | |
| 284,500.00AUD | +394.78% | |
| 57,500.00AUD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bio-Gene Technology Stock analysis
Frequently Asked Questions about Bio-Gene Technology stock
Net Financing Cash Flow of Bio-Gene Technology is 2.74 M AUD in 2026.
Net Financing Cash Flow of Bio-Gene Technology changed from 1.47 M AUD to 2.74 M AUD, representing a 86.41% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Net Financing Cash Flow Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.
Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.
Net Financing Cash Flow's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Bio-Gene Technology historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Bio-Gene Technology
All Key Metrics — Bio-Gene Technology
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth